A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Public ClinicalTrials.gov record NCT02494778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
Study identification
- NCT ID
- NCT02494778
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Prilenia
- Industry
- Enrollment
- 248 participants
Conditions and interventions
Conditions
Interventions
- Pridopidine Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2015
- Primary completion
- Jan 11, 2018
- Completion
- Jan 11, 2018
- Last update posted
- Sep 16, 2021
2015 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12204 | Los Angeles | California | 90095 | — |
| Teva Investigational Site 12201 | Englewood | Colorado | 80113 | — |
| Teva Investigational Site 12196 | Washington D.C. | District of Columbia | 20007 | — |
| Teva Investigational Site 12206 | Baltimore | Maryland | 21287 | — |
| Teva Investigational Site 12200 | Manhasset | New York | 11030 | — |
| Teva Investigational Site 12203 | New York | New York | 10032 | — |
| Teva Investigational Site 12198 | Rochester | New York | 14618 | — |
| Teva Investigational Site 12211 | Winston-Salem | North Carolina | 27157 | — |
| Teva Investigational Site 12209 | Pittsburgh | Pennsylvania | 15213 | — |
| Teva Investigational Site 12208 | Salt Lake City | Utah | 84108 | — |
| Teva Investigational Site 12210 | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02494778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2021 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02494778 live on ClinicalTrials.gov.